HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aluminum-Containing Antiperspirant Renal Warning Mandated By FDA

This article was originally published in The Rose Sheet

Executive Summary

Antiperspirants containing aluminum will be required to carry a renal dysfunction warning due to risks associated with possible increased absorption of the ingredient, according to the OTC Antiperspirant Drug Products Final Monograph

You may also be interested in...



P&G Extends Secret Lineup With Aluminum-Free, Clinical-Strength Formulas

P&G targets Secret Aluminum Free Deodorant, a silicone-based formula, to consumers seeking underarm products without aluminum. Brand also adds Clinical-Strength offering.

P&G Goes Native In Acquisition That Aligns With Peltz' Vision

P&G's purchase of Native deodorants likely is approved by activist investor and potential board member Nelson Peltz, who has pushed the firm to invest in small and local brands as well as natural products. Analysts believe more tuck-in deals could be in the offing to help the firm compete against rising e-commerce startups.

P&G Goes Native In Acquisition That Aligns With Peltz' Recommendations

P&G purchase of Native deodorants likely is approved by activist investor and potential board member Nelson Peltz, who has pushed the firm to invest in small and local brands as well as natural products. It could be first in a series of tuck-in deals to help the firm compete with e-commerce start-ups.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel